Marinomed Biotech: Detailed clinical data show rapid onset of action of Budesolv to alleviate hay

Phase III study comparing Budesolv with standard treatment: Budesolv acts faster against allergic nasal symptoms and asthma-associated symptoms and requires 85% less active ingredient for the same effect.
By: Marinomed Biotech AG
 
 
Spread the Word
Listed Under

Tag:
Marinomed

Industry:
Health

Location:
Vienna - Vienna - Austria

VIENNA - Nov. 26, 2019 - PRLog -- Marinomed Biotech AG (Marinomed) has presented detailed data from its pivotal Phase III clinical trial for the therapeutic comparability of an aqueous solution of budesonide, a synthetic steroid for the treatment of hay fever. A nasal spray, referred to as Budesolv, is the current lead product of the company's Marinosolv® technology platform, which enables complete solubilization of difficult-to-dissolve substances, such as steroids. For the first time detailed evaluations of the data on the treatment of 75 patients were shown at the annual meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Houston, Texas. Allergy patients received Budesolv, Rhinocort Aqua (a licensed, suspension-based comparator) or placebo once daily for 8 days. Patients were exposed to grass pollen under controlled conditions for six hours on the first and last day of treatment. Budesolv contains 10 μg / spray which is approximately 85% less amount of active ingredient than the comparator product (64 μg / spray).

As a summary, the data show that Budesolv is the first steroid nasal spray resulting in a clinically relevant reduction of symptoms – with approximately 50% of the maximum efficacy, within few hours after the first single treatment.

After one week of treatment low dose Budesolv was equally active compared with the originator product Rhinocort Aqua, which requires several days pre-treatment to be effective. Dr. Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed: "This study shows that thanks to our Marinosolv® technology, an aqueous solution of an active substance can be superior to a suspension. In addition, a significantly lower amount of active ingredient is required. This is excellent data, also with regard to our further projects based on the Marinosolv® technology, such as, for example, our product Tacrosolv, a treatment for allergic conjunctivitis and dry eye."


Reference link to detailed data:https://epostersonline.com/acaai2019/node/2212

Further information is available at: www.marinomed.com.

For further enquiries contact:

Dr. Eva Prieschl-Grassauer

Chief Scientific Officer, Marinomed

Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
E-Mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl

Managing Partner, Metrum Communications

Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria

T +43 (0) 1 504 69 87 331

E-Mail: r.mayrl@metrum.at

http://www.metrum.at

Contact
PR&D
***@prd.at
End
Email:***@prd.at Email Verified
Tags:Marinomed
Industry:Health
Location:Vienna - Vienna - Austria
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
PR&D - Public Releations for Research & Education PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share